|Awarded On||November 02, 2011|
|Title||Targeting hedgehog pathway for prostate cancer treatment|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Luzhe Sun|
Prostate cancer (PCa) is the leading cancer diagnosed and the second cause of cancer death in American men. Patients with metastatic prostate cancer (PCa) are often treated first with androgen deprivation therapy, but will invariably develop hormone therapy refractory PCa. Chemotherapy is the frontline of therapy for hormone therapy refractory PCa, but has not been very effective due to the development of chemo-resistance. Furthermore, therapeutic approaches for hormone therapy refractory PCa are very limited. The overall goals of our proposed research are to elucidate how androgen-dependent PCa becomes androgen-independent and resistant to chemotherapy during androgen deprivation therapy...